Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Southern Rhodesia's main contribution to the Burma Campaign in terms of manpower was made by the Rhodesian African Rifles (RAR), a regiment of black troops led by white officers that joined the front at the end of 1944. The colony also made a significant contribution to the Commonwealth forces' command element in Burma, providing white officers and NCOs to the 81st (West Africa), 82nd (West Africa) and 11th (East Africa) Divisions, made up of units from Nigeria, the Gold Coast, the Gambia, Sierra Leone, Kenya, Uganda, Tanganyika, Nyasaland, Northern Rhodesia and the Congo. Almost every African battalion in Burma had white Rhodesian officers and NCOs attached; some were over 70% Rhodesian-led. Modelled on the Rhodesia Native Regiment of World War I, the RAR was formed in May 1940 under the command of Lieutenant-Colonel F J Wane, who the black soldiers nicknamed msoro-we-gomo ("top of the mountain"). Most volunteers for the regiment came from Mashonaland, much to the surprise of the white recruiters, who had expected Matabeleland, with stronger martial traditions, to provide more men. Originally comprising one battalion, the RAR expanded to two battalions in late 1943 to accommodate a rush of new recruits following the news that the 1st Battalion was being deployed overseas.
=== Parachute mitral valve === Parachute mitral valve occurs when all the chordae tendineae of the mitral valve attach to a single papillary muscle. This causes mitral valve stenosis at an early age. It is a rare congenital heart defect. Although it often causes mitral insufficiency, it may not present any symptoms.
=== Liver === Although glyceroneogenesis was first found in adipose tissues, it was not recognized in the liver until 1998. This finding was unexpected because triglyceride synthesis in the liver was thought not to occur due to the amount of gluconeogenesis taking place, and because the liver was believed to have sufficient glycerol 3-phosphate collected from the bloodstream. Several experiments using stable isotopes to track the glycerol in the liver and bloodstream, showed that 65% of the glycerol backbone of triglycerides in the bloodstream is synthesized in the liver. It was subsequently found that the liver synthesizes more than half of the glycerol mammals need to regulate lipids. Glyceroneogenesis in the liver and adipose tissues regulate lipid metabolism in opposite ways. Lipids as triglycerides are released from the liver, while glyceroneogenesis restrains the fatty acid release from adipose tissues by re-esterifying them. When the lipid concentration in the blood is relatively high, glyceroneogenesis in the liver will be down-regulated to stop the synthesis of triglycerides, but glyceroneogenesis in adipose tissues will be induced in order to restrain the release of free fatty acid to the bloodstream. Conversely, glyceroneogenesis is induced in the liver and suppressed in adipose tissues when the blood lipid level is low. Although the reciprocal regulation of glyceroneogenesis is not well understood, a hormone called glucocorticoid is involved in the regulation.
Third, Article 101 of the TFEU prohibits cartels or collusive practices, including competitors engaging in (a) price fixing, (b) limiting production, (c) sharing markets, (d) applying dissimilar conditions to equivalent transactions, and (e) making contracts subject to unconnected obligations. According to Article 101(2) any such agreements between undertakings are automatically void. Article 101(3) establishes exemptions, if the collusion is for distributional or technological innovation, gives consumers a "fair share" of the benefit and does not include unreasonable restraints that risk eliminating competition anywhere. For example, in Parker ITR Srl v Commission eleven corporations that manufactured marine hoses for offshore oil rigs were fined €131 million for rigging bids and sharing markets worldwide – they would designate a "bid champion" in each case to raise prices. Secret cartels are often hard to prove, so the courts allow competition regulators to establish collusion where there is no other plausible explanation for price rises. Some agreements among businesses, however, can be highly beneficial. For instance, in a decision on the Conseil Européen de la Construction d'Appareils Domestiques, the Commission held an agreement among washing machine makers to phase out production of low-efficiency machines was lawful, especially since it would lead to "reduced pollution from electricity generation".
Sources: en.wikipedia.org
Major Crispin Nicholas Black (511814), Welsh Guards. Major Alexander Thomas Boyd (496287), The Royal Logistic Corps. Major Joseph Bright (518051), Adjutant General's Corps (SPS). 24652448 Sergeant (Acting Staff Sergeant) David William Brown, The Royal Logistic Corps. Major Malcolm Hugh Peter Buchanan (495490), The Royal Logistic Corps. 24330851 Warrant Officer Class 1 Andrew Kenneth George Card, The Royal Logistic Corps. Major Steven Cheetham, , (495676), Corps of Royal Engineers (Volunteers), Territorial Army. Acting Lieutenant Colonel John Cobb (448934), Stonyhurst College Combined Cadet Force, Territorial Army. Major Gavin Terence Collinson (501572), The Royal Logistic Corps. 24563002 Staff Sergeant Anthony Raymond Cooper, Adjutant General's Corps (RMP). 24185755 Warrant Officer Class 1 Alan John Crawford, Scots Guards. 24198806 Warrant Officer Class 1 William Crook, Adjutant General's Corps (SPS). 23962020 Staff Sergeant Graham Stuart Daniell, Corps of Royal Electrical and Mechanical Engineers. 24511850 Sergeant (Acting Colour Sergeant) Stephen Denham, The Worcestershire and Sherwood Foresters Regiment. 24072935 Staff Sergeant John James Flannigan, The Light Dragoons. Captain John William Alexander France, , (508406), The Green Howards (Volunteers), Territorial Army. 24750683 Corporal Michael Sean Gill, Corps of Royal Engineers. Major Richard Duncan Brownrigg Gordon (513813), Adjutant General's Corps (ETS). Major Paul Anthony Philip Griffiths (517124) Royal Regiment of Artillery. Captain (Queen's Gurkha Officer) Dharmendra Gurung (537028), The Royal Gurkha Rifles.
=== Heart failure === Although loop diuretics help to treat acute symptoms of heart failure, mineralocorticoid receptor antagonist diuretics (such as spironolactone) can be used long-term to reduce mortality and morbidity associated with certain types of chronic heart failure. A randomized controlled trial in 1999 found that spironolactone reduced death from any cause by 30%, as well as cardiac death and heart failure hospitalisations, in patients with HFrEF on standard therapy. A 2011 randomized controlled trial found similar benefits with eplerenone in HFrEF, supporting the use of mineralocorticoid receptor antagonists in HFrEF when added to contemporary heart failure therapy. Current recommendations from the American Heart Association are to use spironolactone in patients with NYHA Class II-IV heart failure who have a left ventricular ejection fraction of less than 35%. Spironolactone improves left ventricular diastolic function in patients with heart failure with preserved ejection fraction, but it has no effect on mortality and hospitalization. Due to its antiandrogenic properties, spironolactone can cause effects associated with low androgen levels and hypogonadism in males. For this reason, men are typically not prescribed spironolactone for any longer than a short period of time, e.g., for an acute exacerbation of heart failure. A newer medication, eplerenone, has been approved by the US Food and Drug Administration (FDA) for the treatment of heart failure, and lacks the antiandrogenic effects of spironolactone.
STEP 2: The 2-methylpropanol-TPP is oxidized to form an acyl group while being simultaneously transferred to the lipoyl cofactor on E2. Note that TPP is regenerated. The proper arrow-pushing mechanism is shown in Figure 4.
Sources: en.wikipedia.org
The tubers have a crunchy texture and a sweet, nutty flavour. They can be eaten raw, pickled, dried or cooked. A wide range of uses for this vegetable leads to various dishes in the cuisine of many countries. They can be prepared similarly to Jerusalem artichokes. The leaves can be dried and made into a tea. In Chinese and Japanese cuisine, S. affinis is primarily pickled. In particular, its tuber is a part of Osechi, cooked for celebrating Japanese New Year. Dyed red by leaves of Perilla (red shiso) after being pickled, it is called chorogi. In Korea it is called choseokjam (초석잠). In French cuisine, its cooked tuber is often served alongside dishes named japonaise or Japanese-styled.
This glossary of cellular and molecular biology is a list of definitions of terms and concepts commonly used in the study of cell biology, molecular biology, and related disciplines, including genetics, biochemistry, and microbiology. It is split across two articles:
It is a measurement of the contribution of a genotype to the next generation where a value of 1 would be completely selected against and make no contribution and 0 is not selected against at all. This definition of neutral mutation has been criticized due to the fact that very large effective population sizes can make mutations with small selection coefficients appear non neutral. Additionally, mutations with high selection coefficients can appear neutral in very small populations. The testable hypothesis of Kimura and others showed that polymorphism within species are approximately that which would be expected in a neutral evolutionary model. For many molecular biology approaches, as opposed to mathematical genetics, neutral mutations are generally assumed to be those mutations that cause no appreciable effect on gene function. This simplification eliminates the effect of minor allelic differences in fitness and avoids problems when a selection has only a minor effect. Early convincing evidence of this definition of neutral mutation was shown through the lower mutational rates in functionally important parts of genes such as cytochrome c versus less important parts and the functionally interchangeable nature of mammalian cytochrome c in in-vitro studies. Nonfunctional pseudogenes provide more evidence for the role of neutral mutations in evolution. The rates of mutation in mammalian globin pseudogenes has been shown to be much higher than rates in functional genes.
Since its founding in 1517 on the orders of François I, Le Havre has continued to grow: today it measures 27 km (17 mi) from east to west, about 5 km (3 mi) from north to south with an area of 10,000 hectares (24,711 acres). The last big project called Port 2000 increased the handling capacity for containers. The port provides 16,000 direct jobs to the Le Havre region, to which must be added indirect jobs in industry and transport. With approximately 3,000 employees in 2006, the activities of distribution and warehousing provide more jobs, followed by road transport (2,420 jobs) and handling (2,319 jobs). In 2011, 715,279 passengers passed through the port of Le Havre and there were 95 visits by cruise ships carrying 185,000 passengers. The port expects 110 cruise ship calls in 2012. Created in 1934, the leisure boat harbour of Le Havre is located to the west and is the largest French boat harbour in the Channel with a capacity of 1,160 moorings. Finally, there is a small fishing port in the Saint-François district and a Hawker centre.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.